window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

HER2-positive breast cancer

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Affibody advances radioligand therapies for precision oncology

    On World Cancer Day (WCD), Affibody highlights its progress in [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development

    Er-Kim to distribute Nerlynx in CIS and Eastern Europe to improve HER2-positive breast cancer treatment access

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • China biotech growth faces US policy scrutiny despite scientific progress
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Research & Development, Uncategorised
  • FDA allows Medicus Pharma to start SkinJect study in patients with Gorlin Syndrome
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development
  • ViiV Healthcare HIV regimen Dovato non-inferior to Biktarvy in Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top